Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Genflow Biosciences Plc ( (GB:GENF) ) is now available.
Genflow Biosciences plans to seek shareholder approval at a 2 March 2026 general meeting to authorize the issue of up to 188,947,368 new ordinary shares, equivalent to about 38% of its current share capital. The authority would allow the board to undertake a potential non-pre-emptive equity raise via shares or warrants, giving directors flexibility over pricing, allocation, and investor selection.
The company has not yet secured investors or set terms, and there is no certainty the fundraising will proceed, but any proceeds would be directed toward advancing its MASH gene therapy program to IND-enabling stage, completing payments and licensing efforts for its aged-dog clinical trial, glaucoma proof-of-concept and business development work, and key EU and U.S. patent processes. The move underscores Genflow’s need for fresh capital to progress its pipeline and intellectual property portfolio, which could be significant for its positioning in the emerging longevity and age-related therapeutics market.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Spark’s Take on GB:GENF Stock
According to Spark, TipRanks’ AI Analyst, GB:GENF is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
To see Spark’s full report on GB:GENF stock, click here.
More about Genflow Biosciences Plc
Genflow Biosciences Plc is a UK-headquartered, European biotechnology company focused on developing gene therapies for age-related diseases, with R&D facilities in Belgium. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene, with ongoing proof-of-concept work in aged dogs and planned clinical development in MASH, a common chronic liver disease lacking effective treatments.
Average Trading Volume: 1,774,171
Technical Sentiment Signal: Buy
Current Market Cap: £10.36M
Find detailed analytics on GENF stock on TipRanks’ Stock Analysis page.